Taduran, Keisha Kate J.
HRN: 15-62-39 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/24/2023
CEFUROXIME 750MG (VIAL)
03/24/2023
03/30/2023
IVT
670mg
Q8
PCAP C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes